REFERENCES1.
PAAT (Program Against African Trypanosomiasis). Information System. 2006.Online. Available: http://wwwfaoorg/paat/html/gishtm
2.
Rogers DJ, Williams BG:
Monitoring trypanosomiasis in space and time. Parasitology 1993; 106(suppl):S77-S92.
3.
Jordan AM:
Trypanosomiasis Control and African Rural Development,
London, Longman, 1986.
4.
WHO :
Control and surveillance of African trypanosomiasis,
Geneva, World Health Organization, 1998.
5.
Abel PM, Kiala G, Loa V, et al:
Retaking sleeping sickness control in Angola. Trop Med Int Health 2004; 9(1):141-148.
6.
Lutumba P:
Trypanosomiasis control, democratic republic of Congo, 1993-2003. Emerg Infect Dis 2005; 11(9):1382-1389.
7.
Robays J, Bilengue MM, Stuyft PV, et al:
The effectiveness of active population screening and treatment for sleeping sickness control in the Democratic Republic of Congo. Trop Med Int Health 2004; 9(5):542-550.
8.
Ruiz JA, Simarro PP, Josenando T:
Control of human African trypanosomiasis in the Quicama focus, Angola. Bull World Health Organ 2002; 80(9):738-745.
9.
Simarro PP, Franco JR, Ndongo P, et al:
The elimination of Trypanosoma brucei gambiense sleeping sickness in the focus of Luba, Bioko Island, Equatorial Guinea. Trop Med Int Health 2006; 11(5):636-646.
10.
Balasegaram M, Harris S, Checchi F, et al:
Treatment outcomes and risk factors for relapse in patients with early-stage human African trypanosomiasis (HAT) in the Republic of the Congo. Bull WHO 2006; 84:777-782.
11.
Anonymous :
Weekly Epidemiological Record 2006; 8:71-80.
12.
Hoare CA:
The Trypanosomes of Mammals (A Zoological Monograph),
Oxford, Blackwell Scientific, 1972.
13.
Vickerman K:
Antigenic variation in trypanosomes. Nature 1978; 273(5664):613-617.
14.
Buscher P, Bin Shamamba SK, Ngoyi DM, et al:
Susceptibility of Grammomys surdaster thicket rats to Trypanosoma brucei gambiense infection. Trop Med Int Health 2005; 10(9):850-855.
15.
Inoue N, Narumi D, Mbati PA, et al:
Susceptibility of severe combined immuno-deficient (SCID) mice to Trypanosoma brucei gambiense and T. b. rhodesiense. Trop Med Int Health 1998; 3(5):408-412.
16.
Truc P, Aerts D, McNamara JJ, et al:
Direct isolation in vitro of Trypanosoma brucei from man and other animals, and its potential value for the diagnosis of Gambian trypanosomiasis. Trans R Soc Trop Med Hyg 1992; 86(6):627-629.
17.
Dukes P, Kaukas A, Hudson KM, et al:
A new method for isolating Trypanosoma brucei gambiense from sleeping sickness patients. Trans R Soc Trop Med Hyg 1989; 83(5):636-639.
18.
Maina NW, Kunz C, Brun R:
Cryopreservation of Trypanosoma brucei gambiense in a commercial cryomedium developed for bull semen. Acta Trop 2006; 98(3):207-211.
19.
Maina NWN, Oberle M, Otieno C, et al:
Isolation and propagation of Trypanosoma brucei gambiense from sleeping sickness patients in South Sudan. Trans R Soc Trop Med Hyg 2007; 101(6):540-546.
20.
Tomlinson S, Raper J:
Natural human immunity to trypanosomes. Parasitol Today 1998; 14(9):354-359.
21.
Pays E, Vanhollebeke B, Vanhamme L, et al:
The trypanolytic factor of human serum. Nat Rev Microbiol 2006; 4(6):477-486.
22.
Rickman LR, Robson J:
The blood incubation infectivity test: A simple test which may serve to distinguish Trypanosoma brucei from T. rhodesienses. Bull WHO 1970; 42(4):650-651.
23.
Jenni L, Brun R:
A new in vitro test for human serum resistance of Trypanosoma (T.) brucei. Acta Trop 1982; 39(3):281-284.
24.
Radwanska M, Chamekh M, Vanhamme L, et al:
The serum resistance-associated gene as a diagnostic tool for the detection of Trypanosoma brucei rhodesiense. Am J Trop Med Hyg 2002; 67(6):684-690.
25.
Berberof M, Perez-Morga D, Pays E:
A receptor-like flagellar pocket glycoprotein specific to Trypanosoma brucei gambiense. Mol Biochem Parasitol 2001; 113(1):127-138.
26.
Jenni L, Marti S, Schweizer J, et al:
Hybrid formation between African trypanosomes during cyclical transmission. Nature 1986; 322(6075):173-175.
27.
Gibson WC, Mizen VH:
Heritability of the trait for human infectivity in genetic crosses of Trypanosoma brucei ssp. Trans R Soc Trop Med Hyg 1997; 91(2):236-237.
28.
Simo G, Herder S, Njiokou F, et al:
Trypanosoma brucei s.l.: characterisation of stocks from Central Africa by PCR analysis of mobile genetic elements. Exp Parasitol 2005; 110(4):353-362.
29.
Balmer O, Palma C, MacLeod A, et al:
Characterization of di-, tri- and tetranucleotide microsatellite markers with perfect repeats for Trypanosoma brucei and related species. Molecular Ecology Notes 2006; 6:508-510.
30.
Tibayrenc M, Kjellberg F, Ayala FJ:
A clonal theory of parasitic protozoa: the population structures of Entamoeba, Giardia, Leishmania, Naegleria, Plasmodium, Trichomonas, and Trypanosoma and their medical and taxonomical consequences. Proc Natl Acad Sci USA 1990; 87(7):2414-2418.
31.
Gibson W, Miles MA:
Application of new technologies to epidemiology. Brit Med Bull 1985; 41(2):115-121.
32.
Godfrey DG, Baker RD, Rickman LR, et al:
The distribution, relationships and identification of enzymic variants within the subgenus Trypanozoon. Adv Parasitol 1990; 29:1-39.
33.
Stevens JR, Godfrey DG:
Numerical taxonomy of Trypanozoon based on polymorphisms in a reduced range of enzymes. Parasitology 1992; 104:75-86.
34.
Stevens JR, Lanham SM, Allingham R, et al:
A simplified method for identifying subspecies and strain groups in Trypanozoon by isoenzymes. Ann Trop Med Parasitol 1992; 86(1):9-28.
35.
Herder S, Simo G, Nkinin S, et al:
Identification of trypanosomes in wild animals from southern Cameroon using the polymerase chain reaction (PCR). Parasite 2002; 9(4):345-349.
36.
Buyst H:
The epidemiology of sleeping sickness in the historical Luangwa valley. Ann Soc Belge Med Trop 1977; 57(4-5):349-359.
37.
MacLean L, Chisi JE, Odiit M, et al:
Severity of human African trypanosomiasis in East Africa is associated with geographic location, parasite genotype, and host inflammatory cytokine response profile. Infect Immun 2004; 72(12):7040-7044.
38.
Geigy R, Mwambu PM, Kauffmann M:
Sleeping sickness survey in Musoma district, Tanzania. IV. Examination of wild mammals as a potential reservoir for T. rhodesiense. Acta Trop 1971; 28(3):211-220.
39.
De Greef C, Imberechts H, Matthyssens G, et al:
A gene expressed only in serum-resistant variants of Trypanosoma brucei rhodesiense. Mol Biochem Parasitol 1989; 36(2):169-176.
40.
Xong HV, Vanhamme L, Chamekh M, et al:
A VSG expression site-associated gene confers resistance to human serum in Trypanosoma rhodesiense. Cell 1998; 95(6):839-846.
41.
Cibulskis RE:
Genetic variation in Trypanosoma brucei and the epidemiology of sleeping sickness in the Lambwe Valley, Kenya. Parasitology 1992; 104(Part 1):99-109.
42.
Gibson WC, Wellde BT:
Characterization of Trypanozoon stocks from the South Nyanza sleeping sickness focus in Western Kenya. Trans R Soc Trop Med Hyg 1985; 79(5):671-676.
43.
Onyango RJ, van Hoeve K, de Raadt P:
The epidemiology of T. rhodesiense sleeping sickness in Alego location, central Nyanza, Kenya. I. Evidence that cattle may act as reservoir hosts of trypanosomes infective to man. Trans R Soc Trop Med Hyg 1966; 60:175.
44.
Gibson WC, Gashumba JK:
Isoenzyme characterization of some Trypanozoon stocks from a recent trypanosomiasis epidemic in Uganda. Trans R Soc Trop Med Hyg 1983; 77(1):114-118.
45.
Baldry DAT, Chaudhuri MFB:
Epidemiology of African trypanosomiasis. Insect Sci Appl 1980; 1(1):85-93.
46.
Welburn SC, Maudlin I:
Tsetse-trypanosome interactions: rites of passage. Parasitol Today 1999; 15(10):399-403.
47.
Chappuis F, Loutan L, Simarro P, et al:
Options for field diagnosis of human African trypanosomiasis. Clin Microbiol Rev 2005; 18(1):133-146.
48.
Magnus E, Vervoort T, Van Meirvenne N:
A card agglutination test with stained trypanosomes (CATT) for the serological diagnosis of T.b. gambiense trypanosomiasis. Ann Soc Belge Med Trop 1978; 58:169-176.
49.
Chappuis F, Stivalello E, Adams K, et al:
Card agglutination test for trypanosomiasis (CATT) end-dilution titer and cerebrospinal fluid cell count as predictors of human African trypanosomiasis (Trypanosoma brucei gambiense) among serologically suspected individuals in Southern Sudan. Am J Trop Med Hyg 2004; 71:313-317.
50.
Inojosa WO, Augusto I, Bisoffi Z, et al:
Diagnosing human African trypanosomiasis in Angola using a card agglutination test: observational study of active and passive case finding strategies. BMJ 2006; 332(7556):1479.
51.
Simarro PP, Ruiz JA, Franco JR, et al:
Attitude towards CATT-positive individuals without parasitological confirmation in the African Trypanosomiasis (T.b. gambiense) focus of Quicama (Angola). Trop Med Int Health 1999 Dec; 4(12):858-861.
52.
Buscher P, Lejon V, Magnus E, et al:
Improved latex agglutination test for detection of antibodies in serum and cerebrospinal fluid of Trypanosoma brucei gambiense infected patients. Acta Trop 1999; 73(1):11-20.
53.
Deborggraeve S, Claes F, Laurent T, et al:
Molecular dipstick test for diagnosis of sleeping sickness. J Clin Microbiol 2006; 44(8):2884-2889.
54.
Woo PT:
The haematocrit centrifuge for the detection of trypanosomes in blood. Can J Zool 1969; 47(5):921-923.
55.
Lumsden WGR, Kimber CD, Evans DA, et al:
Trypanosoma brucei: Miniature anion exchange centrifugation for detection of low parasitemias: Adaptation for field use. Trans R Soc Trop Med Hyg 1979; 73:313-317.
56.
Doua F, Miezan TW, Sanon Singaro JR, et al:
The efficacy of pentamidine in the treatment of early-late stage Trypanosoma brucei gambiense trypanosomiasis. Am J Trop Med Hyg 1996; 55(6):586-588.
57.
Lejon V, Legros D, Savignoni A, et al:
Neuro-inflammatory risk factors for treatment failure in ‘early second stage’ sleeping sickness patients treated with Pentamidine. J Neuroimmunol 2003; 144(1-2):132-138.
58.
Lejon V, Buscher P:
Cerebrospinal fluid in human African trypanosomiasis: a key to diagnosis, therapeutic decision and post-treatment follow-up [Review Article]. Trop Med Int Health 2005; 10(5):395-403.
59.
Lejon V, Buscher P, Sema NH, et al:
Human African trypanosomiasis: A latex agglutination field test for quantifying IgM in cerebrospinal fluid. Bull WHO 1998; 76(6):553-558.
60.
Lejon V, Legros D, Richer M, et al:
IgM quantification in the cerebrospinal fluid of sleeping sickness patients by a latex card agglutination test. Trop Med Int Health 2002; 7(8):685-692.
61.
Buguet A, Bisser S, Josenando T, et al:
Sleep structure: a new diagnostic tool for stage determination in sleeping sickness. Acta Trop 2005; 93(1):107-117.
62.
Blum J, Schmid C, Burri C:
Clinical aspects of 2541 patients with second stage human African trypanosomiasis. Acta Trop 2006; 97(1):55-64.
63.
Schultzberg M, Ambatsis M, Samuelsson EB, et al:
Spread of Trypanosoma brucei to the nervous system: early attack on circumventricular organs and sensory ganglia. J Neurosci Res 1988; 21(1):56-61.
64.
Pepin J:
African trypanosomiasis.
In: Strickland GT, ed.
Hunter's Tropical Medicine and Emerging Infectious Diseases,
8th edn.. Philadelphia: Saunders; 2000:643-654.
65.
Manson-Bahr PEC, Bell DR:
African Trypanosomiasis. Manson's Tropical Diseases,
19th edn.. London: Baillière and Tindall; 1987:54-73.
66.
Molyneux DH, Pentreath V, Doua F:
African trypanosomiasis in man.
In: Cook GC, ed.
Manson's Tropical Diseases,
20th edn.. London: Saunders; 1996:1171-1196.
67.
Kristensson K, Bentivoglio M:
Pathology of African trypanosomiasis.
In: Dumas M, Bouteille B, Buguet A, ed.
Progress in Human African Trypanosomiasis, Sleeping Sickness,
Paris: Springer; 1999:157-182.
68.
Mansfield JM, Paulnock DM:
Regulation of innate and acquired immunity in African trypanosomiasis. Parasite Immunol 2005; 27(10-11):361-371.
69.
MacLean L, Odiit M, Sternberg JM:
Nitric oxide and cytokine synthesis in human African trypanosomiasis. J Infect Dis 2001; 184(8):1086-1090.
70.
Baetselier PD, Namangala B, Noel W, et al:
Alternative versus classical macrophage activation during experimental African trypanosomosis. Int J Parasitol 2001; 31(5-6):575-587.
71.
Lejon V, Reiber H, Legros D, et al:
Intrathecal immune response pattern for improved diagnosis of central nervous system involvement in trypanosomiasis. J Infect Dis 2003; 187(9):1475-1483.
72.
Sternberg J:
Human African trypanosomiasis: clinical presentation and immune response. Parasite Immunol 2004; 26(11-12):469-476.
73.
Bisser S, Ouwe-Missi-Oukem-Boyer ON, Toure FS, et al:
Harbouring in the brain: A focus on immune evasion mechanisms and their deleterious effects in malaria and human African trypanosomiasis. Int J Parasitol 2006; 36(5):529-540.
74.
Vincendeau P, Bouteille B:
Immunology and immunopathology of African trypanosomiasis. An Acad Bras Cienc 2006; 78(4):645-665.
75.
Berriman M, Ghedin E, Hertz-Fowler C, et al:
The genome of the African trypanosome Trypanosoma brucei. Science 2005; 309(5733):416-422.
76.
El-Sayed NM, Myler PJ, Blandin G, et al:
Comparative genomics of trypanosomatid parasitic protozoa. Science 2005; 309(5733):404-409.
77.
Hutchinson OC, Webb H, Picozzi K, et al:
Candidate protein selection for diagnostic markers of African trypanosomiasis. Trends Parasitol 2004; 20(11):519-523.
78.
Agranoff D, Stich A, Abel P, et al:
Proteomic fingerprinting for the diagnosis of human African trypanosomiasis. Trends Parasitol 2005; 21(4):154-157.
79.
Apted FIC:
Treatment of human trypanosomiasis.
In: Mulligan HW, ed.
The African Trypanosomiasis,
London: Allen & Unwin; 1970:684-710.
80.
Sands M, Kron MA, Brown RB:
Pentamidine: A review. Review in Infectious Diseases 1985; 7:625-634.
81.
Doua F, Yapo FB:
Human trypanosomiasis in the Ivory Coast - therapy and problems. Acta Trop 1993; 54(3-4):163-168.
82.
Bronner U, Doua F, Ericsson O, et al:
Pentamidine concentrations in plasma, whole blood and cerebrospinal fluid during treatment of Trypanosoma gambiense infection in Côte d'Ivoire. Trans R Soc Trop Med Hyg 1991; 85(5):608-611.
83.
Berger BJ, Lombardy RJ, Marbury GD, et al:
Metabolic N-hydroxylation of pentamidine in vitro. Antimicrob Agents Chemother 1990; 34(9):1678-1684.
84.
Wang CC:
Molecular mechanisms and therapeutic approaches to the treatment of African trypanosomiasis. Annu Rev Pharmacol Toxicol 1995; 35:93-127.
85.
Collins JM, Klecker RWJ, Yarchoan R, et al:
Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. J Clin Pharmacol 1986; 26:22-26.
86.
Chijioke CP, Umeh RE, Mbah AU, et al:
Clinical pharmacokinetics of suramin in patients with onchocerciasis. Eur J Clin Pharmacol 1998; 54(3):249-251.
87.
Fairlamb AH, Bowman BR:
Uptake of the trypanocidal drug suramin by bloodstream forms of Trypanosoma brucei and its effect in respiration and growth rate in vivo. J Biochem Pathol 1980; 1:315-333.
88.
Friedheim EAH:
Mel B in the treatment of human trypanosomiasis. Am J Trop Med Hyg 1949; 29:173-180.
89.
Brun R, Schumacher R, Schmid C, et al:
The phenomenon of treatment failures in human African trypanosomiasis. Trop Med Int Health 2001; 6(11):906-914.
90.
Burri C, Nkunku S, Merolle A, et al:
Efficacy of new, concise treatment schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet 2000; 355:1419-1425.
91.
Schmid C, Richer M, Bilenge CM, et al:
Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: Confirmation from a multinational study (Impamel II). J Infect Dis 2005; 191(11):1922-1931.
92.
Jannin J, Cattand P:
Treatment and control of human African trypanosomiasis. Curr Opin Infect Dis 2004; 17(6):565-571.
93.
Blum J, Nkunku S, Burri C:
Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis. Trop Med Int Health 2001; 6(5):390-400.
94.
Soignet SL, Tong WP, Hirschfeld S, et al:
Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia. Cancer Chemother Pharmacol 1999; 44(5):417-421.
95.
Keiser J, Ericsson O, Burri C:
Investigations of the metabolites of the trypanocidal drug melarsoprol. Clin Pharmacol Therapeutics 2000; 67(5):478-488.
96.
Pepin J, Milord F, Mpia B, et al:
An open clinical trial of nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness in central Zaire. Trans R Soc Trop Med Hyg 1989; 83(4):514-517.
97.
Van Nieuwenhove S:
Present strategies in the treatment of human African trypanosomiasis.
In: Dumas M, Bouteille B, Buguet A, ed.
Progress in Human African Trypanosomiasis, Sleeping Sickness,
Paris: Springer; 1999:253-280.
98.
Burri C, Baltz T, Giroud C, et al:
Pharmacokinetic properties of the trypanocidal drug melarsoprol. Chemotherapy 1993; 39(4):225-234.
99.
Chappuis F, Udayraj N, Stietenroth K, et al:
Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis. Clin Infect Dis 2005; 41(5):748-751.
100.
Burri C, Brun R:
Eflornithine for treatment of human African trypanosomiasis. Parasitol Res 2003; 90(suppl 1):S49-S52.
101.
Dow MM:
Ornidyl label. Ornidyl Patient Information 1991.
102.
Bacchi CJ, Nathan HC, Hutner SH, et al:
Polyamine metabolism: a potential therapeutic target in trypanosomes. Science 1980; 210(4467):332-334.
103.
Pegg AE, McCann PP:
Polyamine metabolism and function. Am J Physiol 1982; 243(5):C212-C221.
104.
Gonnert R:
Nifurtimox: causal treatment of Chagas' disease. Drug Res 1972; 22(9):1563.
105.
Priotto G, Fogg C, Balasegaram M, et al:
Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: A randomized clinical trial in Uganda. PLoS Clin Trials 2006; 1(8):e39.1-8.
106.
Wegner DH, Rohwedder RW:
Experience with nifurtimox in chronic Chagas' infection. Preliminary report. Drug Res 1972; 22(9):1635-1641.
107.
Paulos C, Paredes J, Vasquez I, et al:
Pharmacokinetics of a nitrofuran compound, nifurtimox, in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 1989; 27(9):454-457.
108.
Docampo R, Moreno SN:
Free radical metabolism of antiparasitic agents. Fed Proc 1986; 45(10):2471-2476.
109.
Legros D, Evans S, Maiso F, et al:
Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Trans R Soc Trop Med Hyg 1999; 93:439-442.
110.
Stanghellini A, Josenando T:
The situation of sleeping sickness in Angola: a calamity. Trop Med Int Health 2001; 6(5):330-334.
111.
Pepin J, Mpia B:
Trypanosomiasis relapse after melarsoprol therapy, Democratic Republic of Congo, 1982-2001. Emerg Infect Dis 2005; 11(6):921-927.
112.
Burri C, Keiser J:
Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment. Trop Med Int Health 2001; 6(5):412-420.
113.
Matovu E, Enyaru JC, Legros D, et al:
Melarsoprol refractory T.b. gambiense from Omugo, north-western Uganda. Trop Med Int Health 2001; 6(5):407-411.
114.
Matovu E, Geiser F, Schneider V, et al:
Genetic variants of the TbAT1 adenosine transporter from African trypanosomes in relapse infections following melarsoprol therapy. Mol Biochem Parasitol 2001; 117(1):73-81.
115.
Bisser S, Van Nieuwenhove S, Lejon V, et al. New therapeutic regimen for sleeping sickness. Description, results and lessons from the clinical trial established in Bwamanda (Equateur, RDC). Bruges: COST B9 Meeting; 2000.116.
Immtech :
Immtech Report Fiscal Year End 2008 Results.
Online. Available: http://www.immtechpharma.com/documents/news_061808a.pdf117.
Anonymous. $22.6 Million Gates Foundation Grant Targets New Treatment for African Sleeping Sickness. 2006. Online. Available: http://wwwuncedu/news/archives/may06/may06shtml118.
Bouchet B, Legros D, Lee E:
Key indicators for the monitoring and evaluation of control programmes of human African trypanosomiasis due to Trypanosoma brucei gambiense. Trop Med Int Health 1998; 3(6):474-481.
